Gadolinium-complexed Aβ-binding contrast agents for MRI diagnosis of Alzheimer's Disease. (October 2015)

• Record Type: Journal Article
• Authors: Matharu, Balpreet; Spencer, Nick; Howe, Franklyn; Austen, Brian
• Is Part Of: Neuropeptides. Volume 53(2015)
• Page Start: 63
• Page End: 70
• Publication Date: 2015-10
• Subjects: Contrast -- β-Amyloid -- MRI -- Alzheimer's -- Transgenic; Neuropeptides -- Periodicals; Neuropeptides; Neuropeptides -- Périodiques; Neuropeptides; Electronic journals; Periodicals; 572.65
• DOI: 10.1016/j.npep.2015.07.001
• Languages: English
• ISSNs: 0143-4179

Abstract

Abstract: MRI contrast agents, containing peptide sequences that bind β-amyloid and gadolinium ions ligated to DOTA have been synthesized for evaluation in early diagnosis of Alzheimer's Disease in transgenic mice models. A number of brain penetration modifications were incorporated and sufficient amounts of contrast agent in the brain were achieved only by addition of a cationic cell penetration sequence along with the use of microparticle assisted ultrasound activation. In the T1 mode of a MRI scan, the peptide (R2) illuminated areas of brain rich in amyloid plaques. Graphical abstract: